Global Drug Reprofiling Market Growth (Status and Outlook) 2025-2031

September 2025 | 83 pages | ID: G9B4E2678002EN
LP Information

Abstracts

According to this study, the global Drug Reprofiling market size will reach US$ million by 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Drug Reprofiling Industry Forecast” looks at past sales and reviews total world Drug Reprofiling sales in 2024, providing a comprehensive analysis by region and market sector of projected Drug Reprofiling sales for 2025 through 2031. With Drug Reprofiling sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug Reprofiling industry.

This Insight Report provides a comprehensive analysis of the global Drug Reprofiling landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drug Reprofiling portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug Reprofiling market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug Reprofiling and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug Reprofiling.

This report presents a comprehensive overview, market shares, and growth opportunities of Drug Reprofiling market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Orally
• Intravenously

Segmentation by Application:

• Central Nervous Disorders
• Cardiovascular Disorders
• Oncology
• others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Novartis AG
• Abbott Healthcare
• Pfizer
• Johnson & Johnson
• Hoffmann-La Roche
• Sandoz
• Mylan Inc.
• Teva Pharmaceuticals

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Drug Reprofiling Market Size (2020-2031)
  2.1.2 Drug Reprofiling Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Drug Reprofiling by Country/Region (2020, 2024 & 2031)
2.2 Drug Reprofiling Segment by Type
  2.2.1 Orally
  2.2.2 Intravenously
2.3 Drug Reprofiling Market Size by Type
  2.3.1 Drug Reprofiling Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Drug Reprofiling Market Size Market Share by Type (2020-2025)
2.4 Drug Reprofiling Segment by Application
  2.4.1 Central Nervous Disorders
  2.4.2 Cardiovascular Disorders
  2.4.3 Oncology
  2.4.4 others
2.5 Drug Reprofiling Market Size by Application
  2.5.1 Drug Reprofiling Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Drug Reprofiling Market Size Market Share by Application (2020-2025)

3 DRUG REPROFILING MARKET SIZE BY PLAYER

3.1 Drug Reprofiling Market Size Market Share by Player
  3.1.1 Global Drug Reprofiling Revenue by Player (2020-2025)
  3.1.2 Global Drug Reprofiling Revenue Market Share by Player (2020-2025)
3.2 Global Drug Reprofiling Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 DRUG REPROFILING BY REGION

4.1 Drug Reprofiling Market Size by Region (2020-2025)
4.2 Global Drug Reprofiling Annual Revenue by Country/Region (2020-2025)
4.3 Americas Drug Reprofiling Market Size Growth (2020-2025)
4.4 APAC Drug Reprofiling Market Size Growth (2020-2025)
4.5 Europe Drug Reprofiling Market Size Growth (2020-2025)
4.6 Middle East & Africa Drug Reprofiling Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Drug Reprofiling Market Size by Country (2020-2025)
5.2 Americas Drug Reprofiling Market Size by Type (2020-2025)
5.3 Americas Drug Reprofiling Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Drug Reprofiling Market Size by Region (2020-2025)
6.2 APAC Drug Reprofiling Market Size by Type (2020-2025)
6.3 APAC Drug Reprofiling Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Drug Reprofiling Market Size by Country (2020-2025)
7.2 Europe Drug Reprofiling Market Size by Type (2020-2025)
7.3 Europe Drug Reprofiling Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Drug Reprofiling by Region (2020-2025)
8.2 Middle East & Africa Drug Reprofiling Market Size by Type (2020-2025)
8.3 Middle East & Africa Drug Reprofiling Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL DRUG REPROFILING MARKET FORECAST

10.1 Global Drug Reprofiling Forecast by Region (2026-2031)
  10.1.1 Global Drug Reprofiling Forecast by Region (2026-2031)
  10.1.2 Americas Drug Reprofiling Forecast
  10.1.3 APAC Drug Reprofiling Forecast
  10.1.4 Europe Drug Reprofiling Forecast
  10.1.5 Middle East & Africa Drug Reprofiling Forecast
10.2 Americas Drug Reprofiling Forecast by Country (2026-2031)
  10.2.1 United States Market Drug Reprofiling Forecast
  10.2.2 Canada Market Drug Reprofiling Forecast
  10.2.3 Mexico Market Drug Reprofiling Forecast
  10.2.4 Brazil Market Drug Reprofiling Forecast
10.3 APAC Drug Reprofiling Forecast by Region (2026-2031)
  10.3.1 China Drug Reprofiling Market Forecast
  10.3.2 Japan Market Drug Reprofiling Forecast
  10.3.3 Korea Market Drug Reprofiling Forecast
  10.3.4 Southeast Asia Market Drug Reprofiling Forecast
  10.3.5 India Market Drug Reprofiling Forecast
  10.3.6 Australia Market Drug Reprofiling Forecast
10.4 Europe Drug Reprofiling Forecast by Country (2026-2031)
  10.4.1 Germany Market Drug Reprofiling Forecast
  10.4.2 France Market Drug Reprofiling Forecast
  10.4.3 UK Market Drug Reprofiling Forecast
  10.4.4 Italy Market Drug Reprofiling Forecast
  10.4.5 Russia Market Drug Reprofiling Forecast
10.5 Middle East & Africa Drug Reprofiling Forecast by Region (2026-2031)
  10.5.1 Egypt Market Drug Reprofiling Forecast
  10.5.2 South Africa Market Drug Reprofiling Forecast
  10.5.3 Israel Market Drug Reprofiling Forecast
  10.5.4 Turkey Market Drug Reprofiling Forecast
10.6 Global Drug Reprofiling Forecast by Type (2026-2031)
10.7 Global Drug Reprofiling Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Drug Reprofiling Forecast

11 KEY PLAYERS ANALYSIS

11.1 Novartis AG
  11.1.1 Novartis AG Company Information
  11.1.2 Novartis AG Drug Reprofiling Product Offered
  11.1.3 Novartis AG Drug Reprofiling Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Novartis AG Main Business Overview
  11.1.5 Novartis AG Latest Developments
11.2 Abbott Healthcare
  11.2.1 Abbott Healthcare Company Information
  11.2.2 Abbott Healthcare Drug Reprofiling Product Offered
  11.2.3 Abbott Healthcare Drug Reprofiling Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Abbott Healthcare Main Business Overview
  11.2.5 Abbott Healthcare Latest Developments
11.3 Pfizer
  11.3.1 Pfizer Company Information
  11.3.2 Pfizer Drug Reprofiling Product Offered
  11.3.3 Pfizer Drug Reprofiling Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Pfizer Main Business Overview
  11.3.5 Pfizer Latest Developments
11.4 Johnson & Johnson
  11.4.1 Johnson & Johnson Company Information
  11.4.2 Johnson & Johnson Drug Reprofiling Product Offered
  11.4.3 Johnson & Johnson Drug Reprofiling Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Johnson & Johnson Main Business Overview
  11.4.5 Johnson & Johnson Latest Developments
11.5 Hoffmann-La Roche
  11.5.1 Hoffmann-La Roche Company Information
  11.5.2 Hoffmann-La Roche Drug Reprofiling Product Offered
  11.5.3 Hoffmann-La Roche Drug Reprofiling Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Hoffmann-La Roche Main Business Overview
  11.5.5 Hoffmann-La Roche Latest Developments
11.6 Sandoz
  11.6.1 Sandoz Company Information
  11.6.2 Sandoz Drug Reprofiling Product Offered
  11.6.3 Sandoz Drug Reprofiling Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Sandoz Main Business Overview
  11.6.5 Sandoz Latest Developments
11.7 Mylan Inc.
  11.7.1 Mylan Inc. Company Information
  11.7.2 Mylan Inc. Drug Reprofiling Product Offered
  11.7.3 Mylan Inc. Drug Reprofiling Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Mylan Inc. Main Business Overview
  11.7.5 Mylan Inc. Latest Developments
11.8 Teva Pharmaceuticals
  11.8.1 Teva Pharmaceuticals Company Information
  11.8.2 Teva Pharmaceuticals Drug Reprofiling Product Offered
  11.8.3 Teva Pharmaceuticals Drug Reprofiling Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Teva Pharmaceuticals Main Business Overview
  11.8.5 Teva Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Drug Reprofiling Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Drug Reprofiling Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Orally
Table 4. Major Players of Intravenously
Table 5. Drug Reprofiling Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global Drug Reprofiling Market Size by Type (2020-2025) & ($ millions)
Table 7. Global Drug Reprofiling Market Size Market Share by Type (2020-2025)
Table 8. Drug Reprofiling Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Drug Reprofiling Market Size by Application (2020-2025) & ($ millions)
Table 10. Global Drug Reprofiling Market Size Market Share by Application (2020-2025)
Table 11. Global Drug Reprofiling Revenue by Player (2020-2025) & ($ millions)
Table 12. Global Drug Reprofiling Revenue Market Share by Player (2020-2025)
Table 13. Drug Reprofiling Key Players Head office and Products Offered
Table 14. Drug Reprofiling Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Drug Reprofiling Market Size by Region (2020-2025) & ($ millions)
Table 18. Global Drug Reprofiling Market Size Market Share by Region (2020-2025)
Table 19. Global Drug Reprofiling Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global Drug Reprofiling Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas Drug Reprofiling Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas Drug Reprofiling Market Size Market Share by Country (2020-2025)
Table 23. Americas Drug Reprofiling Market Size by Type (2020-2025) & ($ millions)
Table 24. Americas Drug Reprofiling Market Size Market Share by Type (2020-2025)
Table 25. Americas Drug Reprofiling Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas Drug Reprofiling Market Size Market Share by Application (2020-2025)
Table 27. APAC Drug Reprofiling Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC Drug Reprofiling Market Size Market Share by Region (2020-2025)
Table 29. APAC Drug Reprofiling Market Size by Type (2020-2025) & ($ millions)
Table 30. APAC Drug Reprofiling Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe Drug Reprofiling Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe Drug Reprofiling Market Size Market Share by Country (2020-2025)
Table 33. Europe Drug Reprofiling Market Size by Type (2020-2025) & ($ millions)
Table 34. Europe Drug Reprofiling Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa Drug Reprofiling Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa Drug Reprofiling Market Size by Type (2020-2025) & ($ millions)
Table 37. Middle East & Africa Drug Reprofiling Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Drug Reprofiling
Table 39. Key Market Challenges & Risks of Drug Reprofiling
Table 40. Key Industry Trends of Drug Reprofiling
Table 41. Global Drug Reprofiling Market Size Forecast by Region (2026-2031) & ($ millions)
Table 42. Global Drug Reprofiling Market Size Market Share Forecast by Region (2026-2031)
Table 43. Global Drug Reprofiling Market Size Forecast by Type (2026-2031) & ($ millions)
Table 44. Global Drug Reprofiling Market Size Forecast by Application (2026-2031) & ($ millions)
Table 45. Novartis AG Details, Company Type, Drug Reprofiling Area Served and Its Competitors
Table 46. Novartis AG Drug Reprofiling Product Offered
Table 47. Novartis AG Drug Reprofiling Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Novartis AG Main Business
Table 49. Novartis AG Latest Developments
Table 50. Abbott Healthcare Details, Company Type, Drug Reprofiling Area Served and Its Competitors
Table 51. Abbott Healthcare Drug Reprofiling Product Offered
Table 52. Abbott Healthcare Drug Reprofiling Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Abbott Healthcare Main Business
Table 54. Abbott Healthcare Latest Developments
Table 55. Pfizer Details, Company Type, Drug Reprofiling Area Served and Its Competitors
Table 56. Pfizer Drug Reprofiling Product Offered
Table 57. Pfizer Drug Reprofiling Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. Pfizer Main Business
Table 59. Pfizer Latest Developments
Table 60. Johnson & Johnson Details, Company Type, Drug Reprofiling Area Served and Its Competitors
Table 61. Johnson & Johnson Drug Reprofiling Product Offered
Table 62. Johnson & Johnson Drug Reprofiling Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. Johnson & Johnson Main Business
Table 64. Johnson & Johnson Latest Developments
Table 65. Hoffmann-La Roche Details, Company Type, Drug Reprofiling Area Served and Its Competitors
Table 66. Hoffmann-La Roche Drug Reprofiling Product Offered
Table 67. Hoffmann-La Roche Drug Reprofiling Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Hoffmann-La Roche Main Business
Table 69. Hoffmann-La Roche Latest Developments
Table 70. Sandoz Details, Company Type, Drug Reprofiling Area Served and Its Competitors
Table 71. Sandoz Drug Reprofiling Product Offered
Table 72. Sandoz Drug Reprofiling Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Sandoz Main Business
Table 74. Sandoz Latest Developments
Table 75. Mylan Inc. Details, Company Type, Drug Reprofiling Area Served and Its Competitors
Table 76. Mylan Inc. Drug Reprofiling Product Offered
Table 77. Mylan Inc. Drug Reprofiling Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Mylan Inc. Main Business
Table 79. Mylan Inc. Latest Developments
Table 80. Teva Pharmaceuticals Details, Company Type, Drug Reprofiling Area Served and Its Competitors
Table 81. Teva Pharmaceuticals Drug Reprofiling Product Offered
Table 82. Teva Pharmaceuticals Drug Reprofiling Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. Teva Pharmaceuticals Main Business
Table 84. Teva Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Drug Reprofiling Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Drug Reprofiling Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Drug Reprofiling Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Drug Reprofiling Sales Market Share by Country/Region (2024)
Figure 8. Drug Reprofiling Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Drug Reprofiling Market Size Market Share by Type in 2024
Figure 10. Drug Reprofiling in Central Nervous Disorders
Figure 11. Global Drug Reprofiling Market: Central Nervous Disorders (2020-2025) & ($ millions)
Figure 12. Drug Reprofiling in Cardiovascular Disorders
Figure 13. Global Drug Reprofiling Market: Cardiovascular Disorders (2020-2025) & ($ millions)
Figure 14. Drug Reprofiling in Oncology
Figure 15. Global Drug Reprofiling Market: Oncology (2020-2025) & ($ millions)
Figure 16. Drug Reprofiling in others
Figure 17. Global Drug Reprofiling Market: others (2020-2025) & ($ millions)
Figure 18. Global Drug Reprofiling Market Size Market Share by Application in 2024
Figure 19. Global Drug Reprofiling Revenue Market Share by Player in 2024
Figure 20. Global Drug Reprofiling Market Size Market Share by Region (2020-2025)
Figure 21. Americas Drug Reprofiling Market Size 2020-2025 ($ millions)
Figure 22. APAC Drug Reprofiling Market Size 2020-2025 ($ millions)
Figure 23. Europe Drug Reprofiling Market Size 2020-2025 ($ millions)
Figure 24. Middle East & Africa Drug Reprofiling Market Size 2020-2025 ($ millions)
Figure 25. Americas Drug Reprofiling Value Market Share by Country in 2024
Figure 26. United States Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 27. Canada Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 28. Mexico Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 29. Brazil Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 30. APAC Drug Reprofiling Market Size Market Share by Region in 2024
Figure 31. APAC Drug Reprofiling Market Size Market Share by Type (2020-2025)
Figure 32. APAC Drug Reprofiling Market Size Market Share by Application (2020-2025)
Figure 33. China Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 34. Japan Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 35. South Korea Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 36. Southeast Asia Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 37. India Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 38. Australia Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 39. Europe Drug Reprofiling Market Size Market Share by Country in 2024
Figure 40. Europe Drug Reprofiling Market Size Market Share by Type (2020-2025)
Figure 41. Europe Drug Reprofiling Market Size Market Share by Application (2020-2025)
Figure 42. Germany Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 43. France Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 44. UK Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 45. Italy Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 46. Russia Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 47. Middle East & Africa Drug Reprofiling Market Size Market Share by Region (2020-2025)
Figure 48. Middle East & Africa Drug Reprofiling Market Size Market Share by Type (2020-2025)
Figure 49. Middle East & Africa Drug Reprofiling Market Size Market Share by Application (2020-2025)
Figure 50. Egypt Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 51. South Africa Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 52. Israel Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 53. Turkey Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 54. GCC Countries Drug Reprofiling Market Size Growth 2020-2025 ($ millions)
Figure 55. Americas Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 56. APAC Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 57. Europe Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 58. Middle East & Africa Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 59. United States Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 60. Canada Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 61. Mexico Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 62. Brazil Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 63. China Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 64. Japan Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 65. Korea Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 66. Southeast Asia Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 67. India Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 68. Australia Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 69. Germany Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 70. France Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 71. UK Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 72. Italy Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 73. Russia Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 74. Egypt Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 75. South Africa Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 76. Israel Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 77. Turkey Drug Reprofiling Market Size 2026-2031 ($ millions)
Figure 78. Global Drug Reprofiling Market Size Market Share Forecast by Type (2026-2031)
Figure 79. Global Drug Reprofiling Market Size Market Share Forecast by Application (2026-2031)
Figure 80. GCC Countries Drug Reprofiling Market Size 2026-2031 ($ millions)